--- title: What Delayed RSV Vaccination Is Costing the Netherlands description: Delays in RSV vaccination for older adults in the Netherlands have led to significant hospital admissions and economic losses, highlighting urgent implementation needs. image: https://health-ecore.com/hubfs/rsv-1.jpeg --- [Skip to the main content.](https://health-ecore.com/news/what-delayed-rsv-vaccination-costs-the-netherlands#main-content) [![HE\_logo\_fc-35-1](https://health-ecore.com/hs-fs/hubfs/HE_logo_fc-35-1.png?width=1500&height=326&name=HE_logo_fc-35-1.png "HE_logo_fc-35-1")](https://health-ecore.com/) [![Health-Ecore](https://health-ecore.com/hs-fs/hubfs/HE_logo_fc-35.png?width=1772&height=385&name=HE_logo_fc-35.png "Health-Ecore")](https://health-ecore.com/) - [Home](https://health-ecore.com) - [About us](https://health-ecore.com/about-us) - Our work - [Scientific work](https://health-ecore.com/publications) - [RSV web app](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands) - [DRAIGON SLR app](https://slrmadraigon.apps.health-ecore.com/) - [Team](https://health-ecore.com/team) - [News](https://health-ecore.com/news) - [Contact](https://health-ecore.com/contact) Toggle Menu Toggle Menu - [Home](https://health-ecore.com) - [About us](https://health-ecore.com/about-us) - Our work - [Scientific work](https://health-ecore.com/publications) - [RSV web app](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands) - [DRAIGON SLR app](https://slrmadraigon.apps.health-ecore.com/) - [Team](https://health-ecore.com/team) - [News](https://health-ecore.com/news) - [Contact](https://health-ecore.com/contact) [Linkedin](https://www.linkedin.com/company/health-ecore/posts/?feedView=all) 2 min read # What Delayed RSV Vaccination Is Costing the Netherlands [![Picture of Simon van der Pol](https://app.hubspot.com/settings/avatar/6076bb0cafb0b64e016c0b629cc901de) Simon van der Pol](https://health-ecore.com/news/author/simon-van-der-pol) : Published June 2, 2026 [RSV](https://health-ecore.com/news/tag/rsv) [Societal Cost-Benefit Analysis](https://health-ecore.com/news/tag/societal-cost-benefit-analysis) [Vaccination](https://health-ecore.com/news/tag/vaccination) ![What Delayed RSV Vaccination Is Costing the Netherlands](https://health-ecore.com/hs-fs/hubfs/rsv-1.jpeg?width=2400&height=1257&name=rsv-1.jpeg) Every winter, the Respiratory Syncytial Virus (RSV) fills hospital wards. Around 6,000 older adults are admitted with RSV infection in the Netherlands each year — a figure almost certainly conservative, given how rarely RSV diagnostics are applied routinely in clinical practice. Effective vaccines have been available since 2023. Yet programmatic vaccination for adults aged 60 and over has not been implemented. A new report by Health-Ecore quantifies what that delay has meant for hospital capacity, reduced health and unnecessary costs. Over three RSV seasons — 2024–25, 2025–26, and 2026–27 — an estimated 11,177 hospital admissions were (or are expected to be) avoidable, of which approximately 840 required intensive care. That is roughly 3,700 ward beds and 280 ICU admissions per winter that vaccination could have freed. These are not hypothetical numbers: they reflect the expected consequence of choosing to wait. *Averted monetary benefits by component* ![averted\_benefits\_en-png-1](https://health-ecore.com/hs-fs/hubfs/averted_benefits_en-png-1.png?width=2100&height=767&name=averted_benefits_en-png-1.png) RSV admissions concentrate in December through February — exactly when intensive care and ward capacity are already under pressure from influenza and other respiratory infections. The system-level effect of 280 avoidable ICU admissions per season is therefore larger than the number implies: each freed bed has downstream consequences for surgical capacity, care quality, and workforce pressure across the hospital. This component of the burden is not captured in the monetised analysis, and its omission makes the reported benefits conservative. The financial picture is equally clear. Total missed monetary benefits over three seasons amount to €635M (95% CI: €475M–€832M), against estimated programme costs of €293M, yielding net benefits of €341M. Avoided hospitalisation costs — €94M of the €99M in direct medical savings — are the dominant driver on the cost side, underscoring that it is the hospital burden, above all, that makes the economic case. *Societal cost-benefits* | Savings in the medical system | €99M | | --- | --- | | Productivity gains | €33M | | QALY gains (valued at €50k/QALY) | €502M | | Subtotal benefits | €634M | | Vaccination costs\* | €241M | | Administration costs | €52M | | Subtotal costs | €293M | | Net benefits | €341M | *\*: assuming a per dose acquisition cost of €75, which is a sizeable discount from the list price. QALY: Quality-Adjusted Life Year* Beyond hospital admissions, an estimated 3,219 deaths and 69,205 GP visits were also avoidable over the three seasons. The analysis also shows 10,054 QALYs lost, valued at €503M at a threshold of €50,000 per QALY. The Dutch Health Council (*Gezondheidsraad*) concluded in March 2025 that RSV vaccination for older adults is warranted and recommended a programme for adults aged 75 and over and for high-risk groups from age 60. Uncertainty about protection duration has so far prevented a definitive implementation decision. However, each additional season without a programme adds to the hospital burden described here. The economic case is robust across a wide range of assumptions: even at a willingness-to-pay threshold of €20,000 per QALY, net benefits remain positive at €40M.   Download the full report here (Dutch)   *This project was funded by GSK, Moderna, and Pfizer, all producers of RSV vaccines.* [![RSV vaccination: a cost-effective strategy for older adults in the Netherlands](https://health-ecore.com/hubfs/AI-Generated%20Media/Images/RSV%20virus%20colourfull%20healthecore%20colours%20pink%20green%20blue-1.png)](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands) #### [RSV vaccination: a cost-effective strategy for older adults in the Netherlands](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands) [![Picture of Florian Zeevat](https://app.hubspot.com/settings/avatar/73887c1c8e359a90139f5bcfb08aae22) Florian Zeevat](https://health-ecore.com/news/author/florian-zeevat) : 2 October 2025, 09:30:01 CEST RSV vaccination for older adults in the Netherlands is cost-effective, preventing thousands of GP visits and hospitalizations while saving millions... [Public Health](https://health-ecore.com/news/tag/public-health) [Infectious Disease](https://health-ecore.com/news/tag/infectious-disease) [RSV](https://health-ecore.com/news/tag/rsv) [Vaccination](https://health-ecore.com/news/tag/vaccination) [Read More](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands) [![Launch of the vaccination guideline for adults with chronic lung disease](https://health-ecore.com/hubfs/Blog%20images/ChrisBonis_34A9231-lowres-online.jpeg)](https://health-ecore.com/news/launch-of-the-vaccination-guideline-for-adults-with-chronic-lung-disease) #### [Launch of the vaccination guideline for adults with chronic lung disease](https://health-ecore.com/news/launch-of-the-vaccination-guideline-for-adults-with-chronic-lung-disease) [![Picture of Simon van der Pol](https://app.hubspot.com/settings/avatar/6076bb0cafb0b64e016c0b629cc901de) Simon van der Pol](https://health-ecore.com/news/author/simon-van-der-pol) : 25 September 2025, 13:25:48 CEST New national guideline launched to improve vaccination for adults with chronic lung disease, providing clear recommendations to enhance prevention... [Public Health](https://health-ecore.com/news/tag/public-health) [Infectious Disease](https://health-ecore.com/news/tag/infectious-disease) [RSV](https://health-ecore.com/news/tag/rsv) [Chronic Lung Diseases](https://health-ecore.com/news/tag/chronic-lung-diseases) [Vaccination](https://health-ecore.com/news/tag/vaccination) [Pneumococcal](https://health-ecore.com/news/tag/pneumococcal) [COVID-19](https://health-ecore.com/news/tag/covid-19) [Influenza](https://health-ecore.com/news/tag/influenza) [Read More](https://health-ecore.com/news/launch-of-the-vaccination-guideline-for-adults-with-chronic-lung-disease) [![Adjuvanted influenza vaccine is a cost-effective investment for older adults in the Netherlands](https://health-ecore.com/hubfs/Realistic%20Elderly%20Couple%20at%20GP%20Office%20Vaccination%20Consultation-1-1.png)](https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands) #### [Adjuvanted influenza vaccine is a cost-effective investment for older adults in the Netherlands](https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands) [Susan de Braak](https://health-ecore.com/news/author/susan-de-braak) : 3 July 2026, 11:55:01 CEST Adjuvanted influenza vaccines for older adults in the Netherlands are a cost-effective strategy, reducing hospitalizations and healthcare costs... [Vaccination](https://health-ecore.com/news/tag/vaccination) [Influenza](https://health-ecore.com/news/tag/influenza) [Cost-effectiveness analysis](https://health-ecore.com/news/tag/cost-effectiveness-analysis) [Read More](https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands) [![The broader societal impact of Alzheimer's disease in the Netherlands](https://health-ecore.com/hubfs/robina-weermeijer-IHfOpAzzjHM-unsplash-1-1.jpeg)](https://health-ecore.com/news/the-broader-societal-impact-of-alzheimers-disease) #### [The broader societal impact of Alzheimer's disease in the Netherlands](https://health-ecore.com/news/the-broader-societal-impact-of-alzheimers-disease) [![Picture of Simon van der Schans](https://app.hubspot.com/settings/avatar/9be45cf1daa01220a3267c98d955a2b7) Simon van der Schans](https://health-ecore.com/news/author/simon-van-der-schans) : 18 September 2025, 14:57:30 CEST Discover the societal impact of Alzheimer’s in the Netherlands and how new treatments can reduce care needs and costs while improving patient... [Alzheimer's Disease](https://health-ecore.com/news/tag/alzheimers-disease) [Societal Cost-Benefit Analysis](https://health-ecore.com/news/tag/societal-cost-benefit-analysis) [Care Capacity](https://health-ecore.com/news/tag/care-capacity) [Read More](https://health-ecore.com/news/the-broader-societal-impact-of-alzheimers-disease) ![HE\_Invest\_Innovate\_Implement-39](https://health-ecore.com/hs-fs/hubfs/HE_Invest_Innovate_Implement-39.png?width=500&height=36&name=HE_Invest_Innovate_Implement-39.png)   - [Contact details](https://health-ecore.com/contact) - [Privacy policy](https://health-ecore.com/privacy-policy) - [LinkedIn policy](https://health-ecore.com/linkedin-rules) © 2026 Health-Ecore B.V. [Linkedin](https://www.linkedin.com/company/health-ecore/posts/?feedView=all) [GitHub](https://github.com/Health-Ecore) Chamber of Commerce: 72059419 | Tax registration: NL 858968447 B01 Return to top ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Simon van der Pol", "url" : "https://health-ecore.com/news/author/simon-van-der-pol" }, "dateModified" : "2026-06-02T12:20:51.385Z", "datePublished" : "2026-06-02T12:06:53.000Z", "headline" : "What Delayed RSV Vaccination Is Costing the Netherlands", "image" : [ "https://health-ecore.com/hubfs/rsv-1.jpeg" ], "mainEntityOfPage" : { "@id" : "https://health-ecore.com/news/what-delayed-rsv-vaccination-costs-the-netherlands", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://health-ecore.com/hubfs/HE_logo_fc-35.png" }, "name" : "Health-Ecore B.V." } } ``` ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : [ { "@type" : "Person", "name" : "Simon van der Pol", "url" : "https://health-ecore.com/news/author/simon-van-der-pol" } ], "dateModified" : "2026-06-02T12:06:53Z", "datePublished" : "2026-06-02T12:06:53Z", "description" : "Delays in RSV vaccination for older adults in the Netherlands have led to significant hospital admissions and economic losses, highlighting urgent implementation needs.", "headline" : "What Delayed RSV Vaccination Is Costing the Netherlands", "image" : [ "https://26748615.fs1.hubspotusercontent-eu1.net/hubfs/26748615/rsv-1.jpeg" ], "inLanguage" : "en", "keywords" : "RSV, Societal Cost-Benefit Analysis, Vaccination", "mainEntityOfPage" : { "@id" : "https://health-ecore.com/news/what-delayed-rsv-vaccination-costs-the-netherlands", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "name" : "Health-Ecore B.V." } } ```